Medical milestones from Novo Nordisk, BioNxt and Bayer: New hope for millions of patients

Elon Musk calls for cheaper obesity medication – Novo Nordisk benefits

The Danish pharmaceutical company Novo Nordisk (ISIN: DK0062498333) is receiving unexpected support from tech billionaire Elon Musk. The Tesla CEO spoke out in favour of better availability of GLP-1 drugs such as Ozempic and called a price reduction for these drugs the most important lever for improving health in the US. Novo Nordisk is already the market leader in this segment, with a market share of over 30%. However, a healthy diet would be more sensible in the long term. But in the land of opportunity, highly processed food remains the Achilles' heel, leading even 16-year-old teenagers to sue major food companies over chronic health issues. Investors know that quick fixes like injectable or oral weight loss drugs are more popular than permanent dietary changes.

The Company dominates the global market for GLP-1 receptor agonists with products such as Ozempic, Rybelsus, and Wegovy. The potential market for obesity drugs alone is estimated at over USD 50 billion. Novo Nordisk generates more than half of its total sales in the US market, where demand for obesity drugs is growing particularly strongly.

Despite competition from Eli Lilly, Novo Nordisk's broad product portfolio gives it a strategic advantage. In particular, oral formulations such as Rybelsus set the Company apart from competitors that only offer injectable drugs. The Company's strong market position is further bolstered by its geographic expansion into emerging markets such as China, India, and Latin America.

The Company is promoting this expansion with a new research collaboration in India. The partnership with the Sher-i-Kashmir Institute of Medical Sciences, SKIMS, is intended to advance clinical studies in the fields of cardiology, obesity and nephrology. The three-year collaboration will see Novo Nordisk provide resources and expertise while SKIMS will provide clinical research infrastructure and access to patients.

BioNxt Solutions achieves breakthrough in multiple sclerosis drug

BioNxt Solutions (ISIN: CA0909741062) is achieving decisive milestones in the development of its novel therapy for multiple sclerosis (MS). The Company is developing BNT23001, an innovative thin-film formulation of the MS drug cladribine, which is placed under the tongue and thus represents an entirely new route of administration.

Multiple sclerosis is a chronic inflammatory disease of the central nervous system in which the body's own immune system attacks the protective sheath of nerve fibres. The consequences are often severe: MS patients suffer from visual disturbances, paralysis and coordination problems. The new thin-film dosage form solves a key problem: many MS patients have difficulty swallowing tablets.

Current preclinical studies confirm the efficacy: BNT23001 shows a high absorption rate in animal trials and is equivalent in effect to the original drug Mavenclad®. The studies demonstrate the safety of use with no adverse local effects. Production is underway at the GMP-certified partner Gen-Plus GmbH & Co KG in Munich.

The timeline for 2025 has been set: After completion of GMP manufacturing in the second quarter, the submission of the clinical trial application to the European authorities is planned for mid-year. The clinical pilot study will start in the second half of the year and will directly compare BNT23001 with Mavenclad®. The patent position is secured with expected patent grants in Europe, the US and Canada through mid-2025.

The new formulation revolutionises MS therapy through its ease of use and rapid absorption through the oral mucosa. For patients, this means a significant improvement in their daily treatment. BioNxt Solutions is setting new standards in MS therapy.

Bayer starts important study for new cancer therapy of solid tumours

The pharmaceutical company Bayer (ISIN: DE000BAY0017) today announced the start of a Phase I clinical trial for a promising new cancer drug. The active ingredient, known as BAY3498264, is designed to treat certain cancers in which a so-called KRAS mutation is present. KRAS stands for 'Kirsten rat sarcoma viral oncogene' and was named after the German-American pathologist Werner Kirsten. This mutation is prevalent in lung, pancreatic, and bowel cancer and is one of the main drivers of tumour growth. 'The pancreatic cancer treatment market was estimated to be worth USD 2.86 billion in 2023.' It is expected to grow from USD 3.30 billion in 2024 to USD 10.69 billion by 2032 at a compound annual growth rate of 15.8%.

The unique aspect of the new drug is its innovative mechanism of action: it blocks a specific protein called SOS1, which is crucial for the growth of cancer cells. Combined with existing KRAS inhibitors, this new therapy could curb tumour growth even more effectively. Professor Dominik Rüttinger, Head of Oncology Research at Bayer Pharmaceuticals, considers this a significant advancement in cancer therapy.

The development of the drug comes at just the right time: in 2022 alone, nearly 2.5 million new cases of lung cancer were diagnosed worldwide. Experts expect a dramatic increase in both the incidence and mortality of this type of cancer by 2040. With the new active ingredient, Bayer aims to further expand its portfolio in precision oncology and develop targeted treatment options for cancer patients.

Danish pharma giant Novo Nordisk dominates the global market for GLP-1 drugs with over 30% market share. Particularly significant is its expansion into emerging markets such as China and India, as well as its broad product range that includes oral formulations. The potential market for obesity drugs alone is estimated to be worth over USD 50 billion. BioNxt Solutions is developing BNT23001, a revolutionary thin-film formulation for MS patients. The key advantage lies in the sublingual administration, which is a significant improvement, especially for patients with swallowing difficulties. Clinical trials will start in 2025, and the patent position is secured by expected grants in the major markets. Bayer is developing BAY3498264, an innovative anti-cancer agent. Its unique selling point is its novel mechanism of action by blocking the SOS1 protein, which, combined with existing KRAS inhibitors, could more effectively combat tumour growth. The pancreatic cancer treatment market is expected to grow to USD 10.69 billion by 2032.